Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

0.6702 -0.0312 (-4.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024
IVVD stock results show that Invivyd met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
From Invivyd
Via GlobeNewswire
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023
IVVD stock results show that Invivyd missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Invivyd: Q4 Earnings Insights
Via Benzinga
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
From Invivyd
Via GlobeNewswire
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces CEO Transition
Jeremy Gowler appointed Interim CEO 
From Invivyd
Via GlobeNewswire
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
Via Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune System
FDA grants emergency use authorization to Invivyd's Pemgarda (pemivibart), a monoclonal antibody for COVID-19 prevention in immune-compromised adults. Interim trial data revealed. 
Via Benzinga
Exposures COVID-19 Product Safety
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results. 
Via Benzinga
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
From Invivyd
Via GlobeNewswire
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
Apple To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
The biggest pre-market stock movers for Wednesday are ready to go as we break down all of the latest news moving shares today! 
Via InvestorPlace
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
From Invivyd
Via GlobeNewswire
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.